relatively benign substance by its consumers and by the lay population (Topp et al., 1999) . Ecstasy users often describe positive effects when they use the drug, saying they feel "euphoric," "blissful," and "more attached to other people" (Walters, Foy, & Castro, 2002) . Clinical research has demonstrated that ecstasy can cause acute side effects that include: difficulty concentrating, anxiety, depressed mood, dissociation feelings, dry mouth, nausea, insomnia, loss of appetite, and sweating (Baggott, 2002; Liechti, Gamma, & Vollenweider, 2001; Morland, 2000) . It is also well established that ecstasy use can cause hyperthermic syndromes, which might lead to death (Baggott, 2002) . Long-term ecstasy use might lead to neurotoxic consequences (Montoya, Sorrentino, Lukas, & Price, 2002; Morland, 2000) .
Most of the studies about ecstasy users conducted in North America have focused on specific subpopulations, such as college students (Boyd et al., 2003) and club and rave attendees (Fendrich, Wislar, Johnson, & Hubbell, 2003; Gross et al., 2002) . At first, ecstasy was only used by specific subpopulations, especially those initially associated to rave movements (Pedersen & Skrondal, 2002) . During the last decade, rave movements became more popular and ecstasy use has spread into other venues, including at home or at the homes of friends (Degenhardt et al., 2004) . The perception of ecstasy as a relatively benign drug might have accelerated the diffusion process of this drug in the population (Ferrence, 2001) . Lenton et al. (1997) have hypothesized that, as the rave-dance drug culture became more popular, the risk of ecstasy-related harmful effects might increase. After analyzing the drug use habits of 83 rave attendees (76% of them were ecstasy users), these researchers concluded that new ecstasy users have less drug-use experience and have less knowledge about the possible side effects of the drug (Lenton et al., 1997) . Assuming Lenton et al.'s conclusion is valid for the general population, then, when the prevalence of ecstasy use increases in a country, new ecstasy users should be more drug naive than more experienced ecstasy users and the association between ecstasy and other drug use would decrease over time as the prevalence of ecstasy use increases.
Despite the fact that ecstasy use is increasing in North America, little is known about its relationship with other drugs of abuse in the general population. For instance, Gross et al. (2002) described 210 rave attendees in Montreal, Quebec, Canada, and found that first use of ecstasy was mostly preceded by alcohol use, nicotine use, marijuana use, LSD use, psilocybin use, amphetamine use, and cocaine use. Because this was a sample of rave attendees, we cannot generalize these findings to the general population. To our knowledge, no epidemiological study in the United States has addressed co-occurrence of other drug use in ecstasy users. A Norwegian epidemiological study investigated the association of ecstasy use with other drug use. The researchers surveyed 10,812 adolescents living in the city of Oslo (ages 14 -17) and concluded that ecstasy use was often intermingled with the use of marijuana, amphetamines, and heroin. According to their study, first ecstasy use occurred after first use of alcohol, cigarettes, marijuana, and amphetamines, whereas it preceded first heroin use (Pedersen & Skrondal, 1999) . In an Australian national representative sample of adolescents and young adults, ecstasy was most commonly used with alcohol, marijuana, and amphetamines (Degenhardt et al., 2004) .
Studies throughout the world have shown that ecstasy use is increasing and that ecstasy use can occur concurrently with other drug use. However, none of these studies have investigated the patterns of other drug use among ecstasy users across a period of time. We hypothesized that adolescents who started to use ecstasy later in the "epidemic" (i.e., early 2000s) might be more drug naive compared with their counterparts who started using ecstasy early in the "epidemic" (early 1990s). In order to fill this gap in understanding about the use of ecstasy, we set out to (a) estimate changes in ecstasy prevalence over time, (b) To analyze the patterns and prevalence of polydrug use among ecstasy users, we found it useful to compare the co-occurrence of other drug use in ecstasy users versus another group of illegal drug users, for example, marijuana users. This approach has advantages over the comparison of ecstasy users with a population that does not use drugs because marijuana users might share more similarities with ecstasy users than nonusers in the general population. Virtually all ecstasy users have used marijuana. Marijuana is generally considered a gateway drug and its users have made the transition to other drug use. Prevalence of marijuana use in the general population is relatively high, providing a large comparison group and strengthening power. Because power is a function of the sample sizes of both groups that are being compared, having a large comparison group such as marijuana users strengthens the ability to detect differences between groups of drug users. For these reasons, marijuana users are a suitable comparison group for ecstasy users. The comparison of other drug use in ecstasy and marijuana users should help the reader to better understand the extent of other drug involvement among ecstasy users. It is important to stress that we compared ecstasy users with marijuana users who do not use ecstasy, so that ecstasy use among marijuana users would not act as a confounder in the analysis.
Method

Sample and Measures
We analyzed data from the 1995, 1997, 1999, and 2001 National Household Survey on Drug Abuse (NHSDA), which was renamed the National Survey on Drug Use and Health in 2002. The NHSDA is sponsored by SAMHSA and is designed to provide estimates of the prevalence of legal and illegal drug use in the household population (aged 12 and over) of the United States. Surveys have been conducted on a regular basis since 1971. African American, Hispanic American, and young people were oversampled to increase the precision estimates for these groups. Overall response rates were similar across each year and ranged from 80.6% to 92% for household screening (percentage of eligible occupied households among the selected addresses) and 69% to 85.3% for completed interviews. More detailed information about the sampling and survey methodology in the NHSDA can be obtained elsewhere (SAMHSA, 2002 In 1999, the surveys underwent a major redesign, changing from a paper-printed questionnaire to a computer-assisted questionnaire. In 1999, a subsample of the interviews was conducted with the paper-printed questionnaire in order to compare both instruments; this comparison showed that lifetime prevalence estimates of drug use tended to be slightly higher with the computer-assisted interview (Chromy, Davis, Packer, & Gfroerer, 2002 ). Although it is not possible to determine whether increases in prevalence of ecstasy use from 1998 to 1999 were due to an actual increase in prevalence in the population or were the result of changes in survey methods, there are a number of indications suggesting that the increase is real. The increases are consistent with trends observed in the Monitoring the Future Study (in which surveys did not undergo any changes) during 1998 and 1999 (Johnston et al., 2000 (Johnston et al., , 2001a (Johnston et al., , 2001b (Johnston et al., , 2002 Johnston et al., 2003) . Also, changes in prevalence of ecstasy use from 1998 to 1999 in the NHSDA are consistent with general trends observed through 2001. It should be noted that the focus of this article is the associations of ecstasy use with other drug use and demographic characteristics over time. We expect these associations would be less sensitive to changes in survey methodology than would estimates of prevalence (Chilcoat, Lucia, & Breslau, 1999) .
Statistical Analysis
We analyzed demographic data (age, gender, race-ethnicity, and total family income) and drug use variables (lifetime ecstasy and other drug use) for all NHSDA surveys cited above. We performed statistical analysis with STATA 8.0 software (StataCorporation, 2003) and used its survey commands to account for sample weighting and complex survey design. We analyzed association with demographic characteristics and other drug use associations by using weighted chi-square tests and weighted logistic regression models.
Results
Demographic Characteristics of Ecstasy Users
Lifetime ecstasy use increased from 1995 (1.6%) through 2001 (3.6%) in the overall sample, with prevalence twice as high in 2001 compared with 1995 (odds ratio [OR] ϭ 2.2, 95% confidence interval [CI] ϭ 1.8 -2.8). The comparison showed increases from 1995 to 2001 across almost all age categories (ages 12-17: from 1.2% to 3.13%, OR ϭ 2.7, CI ϭ 1.7-4.0; ages 18 -25: from 3.45% to 13.09%, OR ϭ 4.2, CI ϭ 3.2-5.5; ages 26 -34: from 2.8% to 5.99%, OR ϭ 2.2, CI ϭ 1.7-2.9), with the exception of those older than 35 ( Figure 1A ). Analyses of ecstasy use by raceethnicity from years 1995 to 2001 showed that prevalence was higher for Whites compared with African Americans (1995: OR ϭ 8.1, CI ϭ 4.4 -15.0; 2001: OR ϭ 3.3, CI ϭ 2.6 -4.3) and Hispanic Americans (1995: OR ϭ 2.3, CI ϭ 1.5-3.6; 2001: OR ϭ 1.4, CI ϭ 1.2-1.7); however, prevalence of ecstasy use for Whites was not statistically significantly higher than that for "Others" (includes Native Americans, Native Hawaiians, Pacific Islanders, and Asian Americans). However, ecstasy use has increased in all raceethnicities ( Figure 1B ). Across all years, ecstasy use was higher for males compared with females; for example, in 1997 males were two times more likely to be ecstasy users than were females (OR ϭ 2.1, CI ϭ 1.5-2.9). However, for females, prevalence of ecstasy use in 2001 was almost three times higher than it was in 1995 (OR ϭ 2.6, CI ϭ 2.0 -3.4), whereas it was only twice as high in males in 2001 compared with 1995 (OR ϭ 2.0, CI ϭ 1.6 -2.6; Figure 1C ). Comparisons of data from 2001 versus those from 1995 show that lifetime ecstasy use significantly increased in almost all family income classes (less than US$20,000: OR ϭ 2.9, CI ϭ 1.9 -4.4; US$20,000 -US$49,999: OR ϭ 2.2, CI ϭ 1.7-3.0; more than US$75,000: OR ϭ 2.1, CI ϭ 1.1-4.0), with a trend toward increase in those with annual family income of US$50,000 -US$74,999 (OR ϭ 1.6, CI ϭ 1.0 -2.8; Figure 1D ).
Other Drug Use Among Ecstasy Users
To test the hypothesis that the association of ecstasy use with other drug use would become weaker (especially in the younger age groups) as ecstasy use increased over time, we estimated the prevalence of lifetime other drug use in ecstasy users in 1995, 1997, 1999, and 2001 , and compared the prevalence of other drug use among ecstasy users in 2001 versus in 1995 (see Table 1 ). Our hypothesis was confirmed for several of the drug use associations: The comparison of data from 2001 with those of 1995 showed an overall decrease among ecstasy users in cocaine use (OR ϭ 0.6, CI ϭ 0.4 -0.9), LSD use (OR ϭ 0.5, CI ϭ 0.3-0.8), stimulant use (OR ϭ 0.7, CI ϭ 0.5-0.9), and sedative use (from 27.5% in 1995 to 15.0% in 2001, OR ϭ 0.5, CI ϭ 0.3-0.7; not shown in Table 1 ). There was a trend toward decrease in overall heroin use in ecstasy users that was not statistically significant (OR ϭ 0.7, CI ϭ 0.4 -1.1). Overall, prevalence of crack use, inhalant use (50% of ecstasy users in all years; not shown in Table 1 ), and pain killer use (50% of ecstasy users in all years; not shown in Table 1 ) remained stable over time, and the overall prevalence of tranquilizer use was 35% in ecstasy users in 1995, 1997, and 2001 , with a slight increase in use in 1999 compared with 1995 (46%, OR ϭ 1.6, CI ϭ 1.1-2.5; not shown in Table 1 ). Adolescent and young adult ecstasy users in 2001 tended to be more drug naive as compared with their 1995 counterparts: There was a steep decrease in heroin use in adolescent ecstasy users, dropping from 38.9% in 1995 to 7.1% in 2001 (OR ϭ 0.1, CI ϭ 0.04 -0.3), there were decreases in crack use in adolescents (OR ϭ 0.1, CI ϭ 0.04 -0.4) and young adults (OR ϭ 0.5, CI ϭ 0.3-0.9), there were decreases in LSD use in adolescents (OR ϭ 0.1, CI ϭ 0.04 -0.4) and young adults (OR ϭ 0.4, CI ϭ 0.2-0.7), and there was a decrease in sedative use in young adults (from 17.6% in 1995 to 8.6% in 2001, OR ϭ 0.4, CI ϭ 0.2-0.8; not shown in Table 1 ). Comparisons of data from 2001 versus those from 1995 show that there were trends toward decreases in cocaine use in adolescents (OR ϭ 0.5, CI ϭ 0.2-1.2) and young adults (OR ϭ 0.8, CI ϭ 0.5-1.2), but they were not statistically significant. Contrary to our hypothesis, tranquilizer use (not shown in Table 1 ) increased in adolescents (from 11.4% in 1995 to 33.2% in 2001; OR ϭ 3.8, CI ϭ 1.4 -10.9). Almost all ecstasy users used alcohol (from 98.81% in 1999 to 100% in 1995; not shown in Table 1 ) and marijuana from 1995 to 2001 (see Table 1 ).
The data from Table 1 enable Figure 1 ). The lifetime prevalence of heroin use among 12-17-year-old ecstasy users in 1995 was 38.9% but decreased to 9.6% when this cohort was 18 -25 years old in 2001 (see Table 1 ). It appears that the reduction in heroin use among ecstasy users was due to the addition of ecstasy users since 1995 who were much less likely to be heroin users than at the start of this interval. Similar patterns were observed for crack use among ecstasy users, supporting the hypothesis that ecstasy users in this age group who started using ecstasy after 1995 tended to be more drug naive and used less crack and heroin as compared with those who started to use ecstasy earlier.
Other Drug Use in Ecstasy Users Versus Marijuana Users
Given the high degree of co-occurrence of other drug use among ecstasy users, we compared the prevalence of other drug use in ecstasy users with the prevalence of other drug use in marijuana users (who never used ecstasy). Almost all (98%; not shown in Table 1 ) marijuana users also used alcohol. The prevalence of other lifetime drug use was much higher for ecstasy users versus marijuana users (see Table   Figure OR ϭ 0.4, CI ϭ 0.3-0.5; cocaine: OR ϭ 0.7, CI ϭ 0.6 -0.9) and young adult marijuana users (LSD: OR ϭ 0.7, CI ϭ 0.6 -0.8; cocaine: OR ϭ 0.6, CI ϭ 0.5-0.7), which is similar to what occurred in ecstasy users. Although there was a decrease in crack use in adolescent ecstasy users, there was an overall increase in crack use in adolescent marijuana users in 2001 compared with in 1995, mainly due to an increase in crack use among adolescent marijuana users in 1997 (OR ϭ 2.4, CI ϭ 1.2-4.7). Although heroin use decreased in adolescent ecstasy users, it remained stable in marijuana users across all age groups. Sedative use remained stable in marijuana users (prevalence around 6% in all years; not shown in Table 1 ). Dissimilar to the decrease in stimulant use in ecstasy users, overall stimulant use slightly increased in marijuana users in comparisons of data from 2001 versus 1995 (OR ϭ 1.3, CI ϭ 1.1-1.6) and across all age groups. Comparisons of data from 2001 versus 1995 showed that inhalant use (15.8% vs. 14%, OR ϭ 1.2, CI ϭ 1.1-1.3), tranquilizer use (11.9% vs. 9.6%, OR ϭ 1.3, CI ϭ 1.2-1.7), and pain reliever use (16.9% vs. 12.5%, OR ϭ 1.4, CI ϭ 1.6 -2.4) also increased in marijuana users as a whole (results not shown in Table 1 ). Similar to adolescent ecstasy users, there were trends toward tranquilizer use increase in adolescent marijuana users (6.8% in 2001 vs. 3.85% in 1995, OR ϭ 1.9, CI ϭ 0.9 -3.6) as well as in young adult marijuana users (8.9% in 2001 vs. 7.5% in 1995, OR ϭ 1.2, CI ϭ 0.9 -1.6), but they were not statistically significant (not shown in Table 1 ). 
Binge Drinking Among Ecstasy Users Versus Marijuana Users
Although co-occurrence of many other drugs decreased in ecstasy users, binge drinking increased across ecstasy users of all age ranges from 1995 to 2001 (overall from 45.8% in 1995 to 64.0% in 2001, OR ϭ 2.1, CI ϭ 1.5-3.0; see Figure 2 ), a pattern similar to that observed among marijuana users (overall from 29.7% to 33.4%, OR ϭ 1.2, CI ϭ 1.1-1.3; see Figure 3 ). However, considerably more ecstasy users had binge drinking episodes as compared with marijuana users in . For example, in 1999 .3% of the ecstasy users had episodes of binge drinking compared with 35.7% of the marijuana users (OR ϭ 2.7, CI ϭ 2.3-3.3); these numbers in 2001 were 64.0% and 33.4% (OR ϭ 3.5, CI ϭ 3.1-4.0), respectively.
Age of First Ecstasy Use and Other Drug Use
The addition of age of onset of ecstasy use in the 2001 NHSDA enabled a determination of order of onset of ecstasy relative to other drugs (see Table 2 ). Most ecstasy users initiated ecstasy use after they had already tried alcohol and marijuana (94.8% and 88.3%, respectively). Fortyfive percent of ecstasy users had initiated LSD before starting to use ecstasy; 17.4% initiated ecstasy and LSD use in the same year and 37.4% initiated ecstasy before LSD use. On the other hand, most ecstasy users had first used ecstasy at a younger age than they first initiated cocaine, crack, heroin, stimulants, inhalants, pain killers (61.3%), tranquilizers (71.1%), and sedatives (87.8%; the last three drug classes not shown in Table 2 ).
Other Drug Use in Past Year and Past Month Ecstasy Use
Both past year and past month ecstasy use are only available in the 2001 data file. It is interesting to note that overall other lifetime drug use was similar among past year ecstasy users and lifetime ecstasy users. For instance, 61.8% of lifetime ecstasy users used cocaine and 62.9% of past year ecstasy users used this drug. Analogous results were found when we compared crack use (17.6% of lifetime ecstasy users and 15.3% of past year ecstasy users), heroin use (12.2% of lifetime ecstasy users and 10.0% of past year ecstasy users), LSD use (67.0% of lifetime ecstasy users and 60.4% of past year ecstasy users), and stimulant use (38.4% of lifetime ecstasy users and 36.7% of past year ecstasy users). We obtained similar results when we compared lifetime and past year ecstasy users by age group. Overall past month ecstasy users also did not differ from lifetime ecstasy users in other lifetime drug use. However, adolescent (ages 12-17) past month ecstasy users used more cocaine compared with adolescent lifetime ecstasy users (cocaine: 49.02% vs. 33.9%, OR ϭ 2.2, CI ϭ 1.3-3.8).
Discussion
The main findings of our study can be summarized as follows: (a) ecstasy use increased in the U.S. general population from 1995 to 2001 for all age groups, race-ethnicities, genders, and socioeconomic classes; (b) the rate of increase was higher in the younger age groups (especially ages 18 -25) as compared with older age groups; (c) ecstasy users were likely to use many other drugs, including alcohol, marijuana, cocaine, crack, heroin, LSD, and stimulants than were marijuana users; (d) association of ecstasy use with other drug use was strongest early in the "epidemic" and diminished in magnitude as the number of new users increased (e.g., decrease in crack, heroin, and LSD use in adolescent ecstasy users).
Because the focus is on demographic and drug use associations with ecstasy use, it is unlikely that the changes implemented in the NHSDA in 1999 would bias the results of this study. If an increase in the lifetime use of two drugs, such as ecstasy and cocaine, occurred solely as the result of the changes in the NHSDA in 1999, it does not necessarily mean that this would affect the association of these two drugs. If there was a bias, it would likely be in the direction of increasing the association between these drugs. However, in this study, there was a decrease in reporting the use of cocaine, heroin, and LSD among ecstasy users and a decrease in the associations of these drugs with ecstasy use. Therefore, it is unlikely that changes in the NHSDA would have biased the results of this study. It is noteworthy that the lifetime prevalence of ecstasy use for young adults (ages 18 -25) in 2001 was extremely high (13.09%) and was four times higher than it was in 1995. Although the prevalence of ecstasy use was highest among Whites and males, researchers and clinicians should keep in mind that its use has increased in other raceethnicities and in females in the past few years. It is interesting to note that ecstasy use among Hispanic Americans was nearly nonexistent during the 1990s but that there was an increase in the prevalence of use for this group in 1999 and 2001. Future research will determine whether the increase is maintained for this group. Contrary to the belief that ecstasy use is confined to higher social classes (Beck & Rosenbaum, 1994; Peroutka, Newman, & Harris, 1988) , our results showed that ecstasy users belong to all social classes, as defined by annual family income.
According to our results, lifetime ecstasy users tend to be polydrug users; however the pattern of other drug use among ecstasy users seems to have changed during the years. Even though the prevalence of binge drinking was already high in this specific group in 1995, this drinking pattern seems to have become even more common among ecstasy users in recent years, suggesting that ecstasy users, particularly those with a more recent onset, might have a higher risk of developing alcohol disorders. It is not possible to determine whether ecstasy and alcohol use occurred on the same occasions by using the NHSDA data because until 2001 data were collected only for lifetime prevalence of ecstasy use. Our results are similar to those of the Degenhardt et al. (2004) epidemiological study conducted in Australia, in which ecstasy users tended to use alcohol, marijuana, and amphetamines in the same time period. These authors also investigated what kind of drugs ecstasy users used concurrently with ecstasy: 74.7% of the young adults and 54.4% of the adolescents had used alcohol together with ecstasy at least once in the year preceding the interview (Degenhardt et al., 2004) . Topp et al. (1999) analyzed other drug use in a sample of 329 Australian ecstasy users and stated that polydrug use was the norm among their sample, with at least two thirds of their participants using other drugs (including alcohol) either in combination with ecstasy or on the days following ecstasy use. Clinical studies have already shown that the consumption of both alcohol and ecstasy can increase the risk of development of psychopathological problems such as depression, psychotic disorders, cognitive impairment, bulimia, impulse control disorders, and panic attacks (Schifano, DiFuria, Forza, Minicuci, & Bricolo, 1998) .
It is interesting to note that in adolescent ecstasy users there was a significant decrease in lifetime heroin, crack, and LSD use from 1995 through 2001. A similar pattern of decrease in crack and LSD use was observed in young adult ecstasy users. As we hypothesized, those ecstasy users who began using later in the "epidemic" appeared to be more drug naive than those who started using ecstasy early in the "epidemic." This phenomenon could simply be related to the fact that during the 1990s ecstasy use became more easily accepted by conventional adolescents, and, as such, is not restricted to adolescents who have already tried a variety of other drugs and engage in more deviant behaviors (Baggot, 2002; Parker, Aldridge, & Measham, 1998) . On the other hand, the information about adolescents in our sample could be censored. For example, many of these ecstasy users might have recently started using ecstasy and might not have accumulated enough time to initiate use of other drugs, such as cocaine and heroin, subsequent to ecstasy use. According to Lenton et al. (1997) , ecstasy users who have less drug-using experience (i.e., who are more drug naive) are prone to a higher risk of drug-related harmful effects because they tend to have less knowledge about the possibility of ecstasy side effects when compared with more experienced users. This should be taken into account when developing prevention and harm reduction strategies for this population. Although our study focuses on trends in ecstasy use from 1995 to 2001, data from the Monitoring the Future Study show that past year ecstasy use decreased among youth from 2001 to 2003 (Johnston et al., 2003) . If this decreasing pattern of ecstasy use remains in future population surveys (not only in youth, but also in young adults), it will be necessary to investigate whether the adolescents and young adults who will continue to use ecstasy will be polydrug users, thus resembling those who used ecstasy early in the "epidemic." In addition, the factors that determine the maintenance of ecstasy use in a subpopulation of adolescents and young adults while its use decreases need to be addressed in future studies.
In the data files analyzed, we only have information on age of first ecstasy use in the 2001 sample and not in previous years. Our results show that ecstasy users have usually tried this drug after having already tried alcohol and marijuana, and, in some cases, first ecstasy use occurred in the same time period as LSD initiation. In a typical "drug use sequence," initial ecstasy use usually preceded the use of cocaine, inhalants, pain killers, stimulants, tranquilizers, sedatives, crack, and heroin. These results are consistent with epidemiological and clinical studies conducted in other countries (Gross et al., 2002; Pedersen & Skrondal, 1999) .
Past year and past month ecstasy use data are available only in the 2001 file. Prevalence of other drug use among these groups of ecstasy users were similar to prevalence of other drug use in lifetime ecstasy users, with the exception of adolescent past month ecstasy users who used more cocaine as compared with adolescent lifetime ecstasy users. Past year and past month indicators of ecstasy use include both chronic and recent onset ecstasy users who need to be further investigated in future studies.
Despite the fact that ecstasy is seen as a benign substance (Topp et al., 1999) , when we compared other drug use in ecstasy users versus marijuana users who had never tried ecstasy (at least until they were interviewed), there were striking differences: Across all years, the prevalence of all other drug use was much higher among ecstasy users as compared with marijuana users. These results lead us to the following important considerations: (a) ecstasy users in the United States are predominantly polydrug users, which is similar to what was found in epidemiological studies conducted in Europe and Australia (Degenhardt et al., 2004; Pedersen & Skrondal, 1999; Topp et al., 1998) ; (b) ecstasy use is introduced after alcohol and marijuana and before other drugs in a typical drug use sequence; (c) young ecstasy users tend to be more drug naive and, as such, they are more vulnerable to the harmful interactions of ecstasy with other drugs; (c) public health strategies should address the possibility of harmful interactions between ecstasy and other drug use.
Some limitations of our study include the following: (a) Our participants, especially adolescents, might be underreporting their drug use; however, some authors state that underreporting probably remains constant over time (Morral, McCaffrey, & Chien, 2003) and thus should not yield differential patterns of reported co-occurrence over time. If the participants were underreporting their drug use, then the ecstasy and other drug use prevalence would be even higher than the prevalence we obtained; (b) we analyzed ecstasy users as a group, however, there are possible within-group differences that need to be addressed in future studies, and drug use characteristics might be different for chronic and recent onset ecstasy users; (c) data that would help to determine whether ecstasy users are using other drugs on the same occasions they use ecstasy are unavailable; (d) we relied on lifetime prevalence of ecstasy use to conduct our analysis, which is based on participant recall; (e) the methods of administration of the NHSDA were different in the years analyzed, although we suspect that these changes would have little impact on the inference of this study.
Prevention and harm reduction strategies that target ecstasy users are still in their infancy. It is necessary to invest in educational programs in order to prevent adolescents and young adults from using ecstasy, as well as to explain to current ecstasy users both the side effects of the drug and the harmful interactions it has with other drugs. Future studies are needed to identify subgroups among ecstasy users, specifically regular and more problematic ecstasy users.
